Zimmer Biomet (ZBH) came out with quarterly earnings of $1.74 per share, missing the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.65 per share a year ago.
Evaluate the expected performance of Zimmer (ZBH) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet's third-quarter results are likely to reflect the strength in its three business segments, namely Hips, Knees and S.ET.
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?
Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.
In terms of Persona cementless Knee, ZBH is currently witnessing strong uptake of the cementless platform Persona OsseoTi.
Zimmer Biomet (ZBH) announces the acquisition of OrthoGrid to expand its hip portfolio with an AI-driven surgical guidance system.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zimmer Biomet's (ZBH) strategic expansion of international business contributes to the top line in the second quarter.
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $1.82 per share a year ago.